Table 3. Methodological and clinico-pathological data for eligible prognostic studies evaluating p53, smad4 and EGFR.
| Reference | n | HR (95% CI) | Significant | 1° Ab (+ dilution) | IHC +ve | IHC cutoff (%) | Male | Age | N1 | T3/T4 | Well | Mod. | Poor | Adjuvant therapy |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| p53 | ||||||||||||||
| DiGiuseppe et al (1994) | 48 | 1.77 (0.95–3.29) | No | Novocastra CM-1 (1 : 1000) | 26 (54) | NS | 25 (52) | 61 | NS | NS | NS | NS | NS | NS |
| Yokoyama et al (1994) | 57 | 1.75 (1.01–3.02) | Yes | Novocastra DO7 (1 : 100) | 33 (58) | NS | NS | 64 | 25 (45) | 27 (47) | 37 (65) | 20 (35) | NS | |
| Lee et al (1995) | 26 | 1.17 (0.43–3.16) | No | Biogenex CM1 (NS) | 7 (27) | NS | 14 (54) | NS | NS | NS | 2 (8) | 20 (77) | 4 (15) | NS |
| Linder et al (1997) | 48 | 2.71 (1.41–5.20) | Yes | DAKO DO7 (1 : 50) | 22 (46) | >1 | 36 (68) | 66 | 18 (38) | 26 (49) | 5 (9) | 18 (34) | 30 (57) | NS |
| Virkajärvi et al (1997) | 36 | 0.99 (0.46–2.11) | No | Novocastra CM-1 (1 : 1000) | 15 (42) | >1 | 16 (44) | 64 | NS | NS | NS | NS | NS | NS |
| Naka et al (1998) | 32 | 0.84 (0.34–2.10) | No | Novocastra BP53-12 (1 : 50) | 19 (59) | NS | 20 (63) | 65 | 23 (72) | 13 (41) | NS | NS | NS | NS |
| Bold et al (1999) | 70 | 0.62 (0.34–1.12) | No | Oncogene DO1 (NS) | 33 (47) | >25 | 36 (51) | 64 | 38 (54) | NS | 15 (22) | 37 (56) | 15 (22) | 19 (27) |
| Gansauge et al (1999) | 26 | 2.97 (1.30–6.79) | Yes | Oncogene DO1 (1 : 500) | 11 (42) | NS | 12 (50) | 59 | 22 (85) | NS | NS | NS | NS | 26 (100) |
| Ahrendt et al (2000) | 43 | 0.77 (0.39–1.52) | No | DAKO DO7 (1 : 2000) | 26 (60) | >33 | 24 (55) | 63 | 23 (53) | 22 (51) | 11 (26) | 23 (55) | 8 (19) | 29 (66) |
| Bergan et al (2000) | 60 | 2.16 (1.14–4.08) | Yes | Novocastra DO7 (1 : 100) | 15 (25) | >5 | 41 (50) | 62 | 18 (30) | 21 (35) | 25 (42) | 23 (38) | 12 (20) | 0 (0) |
| Kawesha et al (2000) | 157 | 0.90 (0.64–1.26) | No | DAKO DO7 (1 : 300) | 64 (41) | >5 | 100 (64) | 60 | 71 (46) | NS | 21 (13) | 77 (49) | 59 (38) | 13 (8) |
| Gerdes et al (2002) | 40 | 1.16 (0.61–2.21) | No | DAKO DO7 (1 : 400) | 13 (33) | >10 | 22 (55) | NS | 16 (40) | NS | NS | NS | NS | 0 (0) |
| Sarela et al (2002) | 52 | 0.53 (0.11–2.53) | No | DAKO DO7 (1 : 100) | 28 (54) | >10 | 27 (52) | 64 | 40 (78) | 49 (94) | 11 (22) | 24 (47) | 16 (31) | NS |
| Yamasawa et al (2002) | 72 | 1.01 (0.62–1.66) | No | Oncogene DO1 (2 μg/ml) | 34 (47) | >20 | 34 (47) | 65 | 21 (29) | 42 (58) | 35 (49) | 32 (44) | 5 (7) | 41 (57) |
| Dong et al (2005a) | 59 | 1.02 (0.60–1.73) | No | DAKO DO7 (1 : 20) | 40 (68) | >10 | 38 (64) | NS | 47 (80) | NS | 19 (32) | 21 (36) | 19 (32) | NS |
| Magistrelli et al (2006) | 67 | 0.68 (0.40–1.16) | No | DAKO DO7 (1 : 50) | 32 (48) | >5 | 45 (67) | 63 | 34 (51) | 40 (62) | 14 (21) | 28 (42) | 15 (22) | 30 (45) |
| Jinfeng et al (2007) | 32 | 3.18 (1.30–7.77) | Yes | DAKO DO7 (1 : 50) | 13 (41) | >10 | 19 (59) | 63 | 18 (56) | 23 (72) | 11 (34) | 18 (56) | 3 (10) | NS |
| smad4 | ||||||||||||||
| Tascilar et al (2001) | 249 | 0.74 (0.56–0.98) | Yes | Santa Cruz B8 (1 : 100) | 111 (46) | NS | 139 (56) | 65 | NS | NS | NS | NS | NS | NS |
| Biankin et al (2002) | 45 | 2.38 (1.08–5.24) | Yes | Santa Cruz B8 (NS) | 10 (22) | >5 | 27 (60) | 61 | 21 (47) | NS | 5 (11) | 28 (62) | 12 (27) | 8 (16) |
| Hua et al (2003) | 34 | 0.94 (0.43–2.08) | No | Santa Cruz B8 (1 : 100) | 26 (76) | NS | 22 (65) | 55 | 14 (41) | NS | 27 (79) | 7 (21) | NS | |
| Toga et al (2004) | 88 | 0.51 (0.27–0.97) | Yes | Santa Cruz B8 (1 : 100) | 13 (15) | >10 | 43 (49) | 66 | 78 (89) | 33 (37) | 37 (42) | 45 (51) | 6 (7) | 58 (66) |
| Khorana et al (2005) | 124 | 0.88 (0.59–1.31) | No | Santa Cruz (1 : 400) | 59 (48) | >5 | 69 (56) | 67 | 56 (45) | 69 (58) | 23 (19) | 52 (43) | 45 (38) | 88 (79) |
| EGFR | ||||||||||||||
| Dong et al (1998a) | 57 | 1.09 (0.51–2.32) | No | Oncogene 985/996 (1 : 20) | 39 (68) | NS | 20 (35) | 55 | 46 (81) | NS | 18 (32) | 22 (39) | 17 (30) | 7 (12) |
| Ueda et al (2004) | 76 | 2.25 (1.14–4.45) | Yes | Zymed 31G7 (1 : 200) | 47 (62) | >10 | 57 (75) | 63 | 59 (78) | NS | 11 (14) | 32 (42) | 33 (43) | NS |
| Bloomston et al (2006) | 71 | 0.79 (0.47–1.34) | No | Dakocytomation 218C9 (NS) | 49 (69) | >1 | 40 (56) | 65 | 41 (58) | 57 (81) | 6 (9) | 45 (63) | 20 (28) | NS |
| Smeenk et al (2007) | 46 | 1.93 (0.92–4.07) | No | DAKO H11 (NS) | 11 (24) | >1 | 37 (66) | 63 | 29 (52) | 34 (61) | 6 (11) | 43 (77) | 7 (12) | 19 (34) |
Abbreviations: CI=confidence interval; EGFR=epidermal growth factor receptor; HR=hazard ratio; IHC=immunohistochemical; NC=non-commercial; NS=not specified.
% in parentheses unless otherwise stated. IHC and/or clinico-pathological data were incompletely reported in some studies. Well/Mod./Poor refers to tumour differentiation.